[go: up one dir, main page]

CR20170384A - Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos - Google Patents

Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos

Info

Publication number
CR20170384A
CR20170384A CR20170384A CR20170384A CR20170384A CR 20170384 A CR20170384 A CR 20170384A CR 20170384 A CR20170384 A CR 20170384A CR 20170384 A CR20170384 A CR 20170384A CR 20170384 A CR20170384 A CR 20170384A
Authority
CR
Costa Rica
Prior art keywords
nucleosids
derivatives
antineoplasic agents
replaced
useful
Prior art date
Application number
CR20170384A
Other languages
English (en)
Inventor
John Howard Tatlock
Eugene Yuanjin Rui
Robert Arnold Kumpf
Martin James Wythes
Michele Ann Mctigue
Indrawan James Mcalpine
Michelle Bich Tran-Dube
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20170384A publication Critical patent/CR20170384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos de la Fórmula general (I): procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos y los usos de estos compuestos.
CR20170384A 2015-02-24 2016-02-15 Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos CR20170384A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US201662279209P 2016-01-15 2016-01-15
PCT/IB2016/050803 WO2016135582A1 (en) 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
CR20170384A true CR20170384A (es) 2017-11-16

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170384A CR20170384A (es) 2015-02-24 2016-02-15 Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos

Country Status (29)

Country Link
US (1) US10428104B2 (es)
EP (1) EP3262057B1 (es)
JP (1) JP6584521B2 (es)
KR (1) KR20170119705A (es)
CN (1) CN107278205A (es)
AU (2) AU2016225133B2 (es)
BR (1) BR112017017396A2 (es)
CA (1) CA2921314A1 (es)
CL (1) CL2017002155A1 (es)
CO (1) CO2017008403A2 (es)
CR (1) CR20170384A (es)
CU (1) CU20170105A7 (es)
DO (1) DOP2017000195A (es)
EA (1) EA031895B1 (es)
ES (1) ES2792899T3 (es)
GT (1) GT201700189A (es)
IL (1) IL253637A0 (es)
MX (1) MX2017010844A (es)
NI (1) NI201700095A (es)
PE (1) PE20171449A1 (es)
PH (1) PH12017501413A1 (es)
SG (1) SG11201706050WA (es)
SV (1) SV2017005514A (es)
TN (1) TN2017000357A1 (es)
TW (1) TWI622595B (es)
UA (1) UA118315C2 (es)
UY (1) UY36564A (es)
WO (1) WO2016135582A1 (es)
ZA (1) ZA201705092B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
JP6909799B2 (ja) * 2016-03-10 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための置換ヌクレオシドアナログ
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
SI3512857T1 (sl) 2016-09-14 2021-07-30 Janssen Pharmaceutica Nv Spiro biciklični zaviralci interakcije menin-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
AU2017338269B2 (en) 2016-10-03 2021-03-25 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
WO2018152548A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018154104A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3939986A1 (en) * 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
BR112020010815A2 (pt) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos
CU24621B1 (es) 2017-12-13 2022-09-08 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7328241B2 (ja) * 2018-03-14 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
KR20210129051A (ko) * 2019-02-13 2021-10-27 프렐루드 테라퓨틱스, 인코포레이티드 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
CA3134779A1 (en) * 2019-03-25 2020-10-01 California Institute Of Technology Prmt5 inhibitors and uses thereof
US12440506B2 (en) 2019-04-05 2025-10-14 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
PH12021553082A1 (en) 2019-06-10 2023-09-11 Lupin Ltd Prmt5 inhibitors
KR20220019766A (ko) 2019-06-12 2022-02-17 얀센 파마슈티카 엔.브이. 신규 스피로바이사이클릭 중간체
PL4299135T3 (pl) 2019-06-18 2025-11-12 Pfizer Inc. Pochodne benzizoksazolosulfonamidu
EP4031555A1 (en) 2019-09-18 2022-07-27 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP7624985B2 (ja) 2019-10-22 2025-01-31 ルピン・リミテッド Ｐｒｍｔ５阻害剤の組合せ医薬
CN115135651A (zh) 2019-12-03 2022-09-30 鲁皮恩有限公司 作为prmt5抑制剂的被取代的核苷类似物
IL293965A (en) 2019-12-19 2022-08-01 Janssen Pharmaceutica Nv History of Spiro straight chain transformed
CA3192099A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
WO2022040172A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
JP2024526762A (ja) 2021-07-12 2024-07-19 インサイト・コーポレイション Ｊａｋ阻害剤を調製するためのプロセス及び中間体
US20250188110A1 (en) * 2021-08-13 2025-06-12 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
CA2495370A1 (en) * 2002-08-15 2004-02-26 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
EP2623104A1 (en) * 2009-03-20 2013-08-07 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
WO2013009735A1 (en) * 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
EP3160477A4 (en) * 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
WO2017024310A1 (en) * 2015-08-06 2017-02-09 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Also Published As

Publication number Publication date
ES2792899T3 (es) 2020-11-12
PE20171449A1 (es) 2017-10-02
SV2017005514A (es) 2018-04-11
EA201791563A1 (ru) 2018-01-31
CU20170105A7 (es) 2017-10-05
IL253637A0 (en) 2017-09-28
TW201643176A (zh) 2016-12-16
EP3262057A1 (en) 2018-01-03
UY36564A (es) 2016-09-30
EA031895B1 (ru) 2019-03-29
AU2016225133A1 (en) 2017-08-10
SG11201706050WA (en) 2017-09-28
AU2016225133B2 (en) 2018-11-29
WO2016135582A1 (en) 2016-09-01
KR20170119705A (ko) 2017-10-27
ZA201705092B (en) 2019-06-26
AU2018278842A1 (en) 2019-01-03
US20160244475A1 (en) 2016-08-25
UA118315C2 (uk) 2018-12-26
TWI622595B (zh) 2018-05-01
BR112017017396A2 (pt) 2018-04-03
TN2017000357A1 (en) 2019-01-16
CL2017002155A1 (es) 2018-05-11
NI201700095A (es) 2017-10-31
CA2921314A1 (en) 2016-08-24
EP3262057B1 (en) 2020-04-15
GT201700189A (es) 2019-06-10
MX2017010844A (es) 2017-12-07
DOP2017000195A (es) 2017-10-15
CN107278205A (zh) 2017-10-20
PH12017501413A1 (en) 2018-01-29
CO2017008403A2 (es) 2017-10-31
US10428104B2 (en) 2019-10-01
JP6584521B2 (ja) 2019-10-02
JP2018510850A (ja) 2018-04-19

Similar Documents

Publication Publication Date Title
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CR20190566A (es) Inhibidores de quinasay usos de los mismos
CL2017002650A1 (es) Compuestos novedosos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
ECSP16074478A (es) Compuestos novedosos
SV2018005657A (es) "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
MX2017008373A (es) Compuestos, composiciones y metodos.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX375725B (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.